Definium Therapeutics, Inc. $DFTX Shares Purchased by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Definium Therapeutics stake by 61.3% in the third quarter, adding 67,618 shares to hold 178,006 shares worth about $6.8 million. Institutional investors and hedge funds own 27.91% of the stock.
• Definium reported quarterly EPS of -$1.44, missing analysts’ estimate of -$0.55. Analysts’ consensus remains “Moderate Buy,” with a $66 average price target.
• Company insiders sold 71,098 shares worth approximately $2.63 million over the past 90 days; CEO and CFO sales cited in the article were made under pre-arranged trading plans.

Alps Advisors Inc. lifted its stake in Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 61.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 178,006 shares of the company's stock after purchasing an additional 67,618 shares during the quarter. Alps Advisors Inc. owned 0.13% of Definium Therapeutics worth $6,775,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Commonwealth Equity Services LLC lifted its holdings in shares of Definium Therapeutics by 4.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company's stock valued at $374,000 after buying an additional 382 shares during the last quarter. TFB Advisors LLC lifted its stake in Definium Therapeutics by 2.5% in the third quarter. TFB Advisors LLC now owns 22,064 shares of the company's stock valued at $840,000 after acquiring an additional 541 shares during the last quarter. Chicago Partners Investment Group LLC lifted its stake in Definium Therapeutics by 16.9% in the third quarter. Chicago Partners Investment Group LLC now owns 8,535 shares of the company's stock valued at $304,000 after acquiring an additional 1,236 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Definium Therapeutics in the third quarter valued at approximately $261,000. Finally, Profund Advisors LLC grew its position in Definium Therapeutics by 216.0% in the third quarter. Profund Advisors LLC now owns 42,885 shares of the company's stock worth $1,632,000 after acquiring an additional 29,314 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Definium Therapeutics Price Performance

NASDAQ DFTX opened at $33.27 on Monday. Definium Therapeutics, Inc. has a twelve month low of $10.46 and a twelve month high of $49.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The stock has a market capitalization of $4.47 billion, a PE ratio of -9.70 and a beta of 2.23. The stock has a 50-day simple moving average of $36.60 and a 200 day simple moving average of $29.95.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). Research analysts anticipate that Definium Therapeutics, Inc. will post -3.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Definium Therapeutics in a research report on Thursday, October 15th. Canaccord Genuity Group set a $78.00 target price on Definium Therapeutics and gave the company a "buy" rating in a report on Tuesday, September 15th. Oppenheimer restated an "outperform" rating and set a $75.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. Finally, Wall Street Zen cut Definium Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.00.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 31,550 shares of the firm's stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $1,153,783.50. Following the sale, the chief executive officer owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the firm's stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the completion of the sale, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. The trade was a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 71,098 shares of company stock valued at $2,626,115 over the last ninety days. 2.40% of the stock is owned by insiders.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.